Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder

Vijaya Raj Bhatt, Fausto R. Loberiza, Pavankumar Tandra, Jairam Krishnamurthy, Rajesh Shrestha, Jue Wang

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


The risk factors, the optimal therapy and prognostic factors contributing to poor outcomes of neuroendocrine urinary bladder carcinoma are not fully elucidated because of its rarity. We reviewed the medical records of neuroendocrine bladder carcinoma patients treated at the University of Nebraska Medical Center between 1996 and 2011. Eighteen patients, 55% female with a median age of 77 years, had stage IV disease at diagnosis in 50% of cases. There was a high prevalence of smoking (78%), medical co-morbidities (94%), prior cancer history (22%) and family history of cancer (61%). Treatment modalities included surgery (72%), platinum-based chemotherapy (50%) and/or radiation (22%). Median overall survival was 18.5 months (95% confidence interval, 7-36 months). Patients with Stage II and III cancer who underwent radical surgery with or without neoadjuvant chemotherapy had a median survival of 37 months. In addition to smoking, for the first time, our study indicates that the personal or family history of cancer may increase risk to neuroendocrine bladder cancer. Advanced age and stage at diagnosis, and the presence of multiple co-morbidities contribute to poor overall survival. Patients with early-stage disease are likely to benefit from a combination of radical surgery and platinum-based neoadjuvant chemotherapy.

Original languageEnglish (US)
Pages (from-to)10-14
Number of pages5
JournalRare Tumors
Issue number1
StatePublished - Jan 23 2014


  • Chemotherapy
  • Family history
  • Large cell neuroendocrine carcinoma of urinary bladder
  • Radical surgery
  • Small cell urinary bladder carcinoma
  • Smoking

ASJC Scopus subject areas

  • Histology
  • Oncology


Dive into the research topics of 'Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder'. Together they form a unique fingerprint.

Cite this